CD44 and cancer: Importantly, we were able to validate these findings using low-passage cancer cell lines (UM18 and UM59) derived from human primary PDA samples, where silencing of ATDC significantly inhibited CD44, Snail1, and Zeb1 expression (Supplemental Fig. 12D).